There’s not much new here from this report from last week’s Movement Disorder Society conference in Vancouver. This report focuses on two anti-tau drugs being studied in PSP — one from AbbVie and one from Bristol-Myers Squibb. The BMS drug was recently licensed to Biogen. Both drugs proved safe in phase I studies, and both have moved into phase II trials.
Tau is the protein involved in PSP and CBD. It’s one of two proteins involved in Alzheimer’s.
Here’s a link to the report: (you have to register — no charge to do so — at Medpage Today to read the article)
Meeting Coverage > MDS
Anti-Tau Drugs for PSP Move into Phase II
But phase I study of one agent pulled from presentation
by Kristina Fiore, Deputy Managing Editor, MedPage Today
June 08, 2017